Chelation therapy is an outpatient treatment method for the treatment of arteriosclerosis and circulatory disorders. Clinical experience with more than 1,000,000 patients worldwide, scientific publications and books prove their excellent effect. The body is given a solution containing various minerals and vitamins, but especially the active ingredient EDTA (ethylenediaminetetraacetic acid).
EDTA has the property of binding heavy metals such as cadmium (cigarettes), lead (gasoline residues) and mercury (amalgam fillings) etc. as well as the light metal calcium in the body, so that these substances can be excreted via the kidneys. Therefore EDTA is excellently suited for metal poisoning as well as for the treatment of arteriosclerosis.
Crucially, EDTA has a strong ability to bind to the so-called transfer metals, which can be aids in the formation of excess free radicals. This arrests arteriosclerosis, restores cell function and reduces calcium overload. The protein-bound calcium remains unaffected by EDTA.
Chelation therapy is practiced throughout the world. Over a thousand doctors in the US have specialized in this field.
The history of chelation therapy goes back to the research work of the Swiss chemist and Nobel laureate Alfred Werner (1866-1919). His concept of the bonding of metals in the molecule opened the new field of complex chemistry. In the 1930s, based on these findings, a white, crystalline, water-soluble powder was developed in Germany, which was excellently suitable as a color stabilizer due to its calcium-binding properties. Several decades later, the usefulness of this powder was also discovered in medicine. Apparently with EDTA also vessels could be “decalcified”.
EDTA is a for humans non-toxic substance that has the ability to form stable complexes with metal ions, which can then be excreted naturally via the kidneys. Chelation therapy is therefore used not only for acute heavy metal poisoning with mercury, lead, cadmium, etc., but above all for the therapy and prevention of arteriosclerosis. Because even calcium, which is incorporated into the arteriosclerotic plaques, is a metal ion. Here, the effect of EDTA has often been compared with the decalcification of pipes. While this is true at the core, it certainly is greatly simplified, as the mechanisms of action of EDTA are more complex and multi-layered.
The scientific basis for today’s practice of chelation therapy has been delivered in recent years by other branches of medicine such as orthomolecular medicine, enzyme therapy, cancer and rheumatism, and the physiology and biochemistry of metabolism and oxygenation in chronic degenerative diseases. Research results from these areas have shown that degenerative diseases and aging processes have a common cause: the excessive formation of the so-called free radicals.
Free radicals are particularly reactive atoms or molecules that arise when overloading combustion processes in the cell. This happens especially when e.g. Heavy metals burden the cell metabolism, but also by UV or X-rays from the outside. Radicals play an important role in a variety of biological processes, but can also cause cell damage if they are not effectively “intercepted”. For example, damage to the genetic material of cells by free radicals, amongst others, are the cause of cancer. But also atherosclerosis and degenerative diseases such as Alzheimer’s disease are attributed to this disease mechanism.
The costs of the therapy can be found in our price list and include all additives (vitamins, trace elements, etc.). The price is mainly due to the duration of several hours and the monitoring of the infusion. Thus, the total cost depends on the severity of the disease and the corresponding number of necessary applications.
Occasionally, minor pain, fatigue, changes in blood pressure, or blood sugar levels may occur during infusion. They are easily controlled by slowing the rate of infusion. Most of the time these side effects disappear after 2 sessions.
A thorough medical examination before starting therapy is mandatory.
A complete chelation therapy involves a minimum of 10-20 single infusions. In advanced cases of arteriosclerosis and arterial occlusion usually much more sessions are required (30 to 100 infusions). The infusions are done 1 to 3 times a week and must be given very slowly. A therapy session lasts on average 3-4 hours. If a burning occurs during the infusion from the puncture site upwards, the infusion rate is further reduced.
Chelation therapy can also be used with other forms of arterial occlusive therapy. It is compatible with the concomitant administration of “blood thinners” and medications that dilate blood vessels, lower blood pressure, or counter cardiac arrhythmias. Often, during or after a successful chelation therapy, you can partially or completely stop taking certain medications. Chelation therapy is also possible after vascular surgery or amputations. The aim of this therapy, however, is precisely to prevent such serious interventions.